🇺🇸 FDA

Drug profile · INN

nogapendekin alfa inbakicept-pmln

ANKTIVA

FDA: approved
US status
approved
Patents linked
0
News articles
1

Quick answer

nogapendekin alfa inbakicept-pmln (ANKTIVA) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravesical. Current US regulatory status: approved.

Key facts

INN nogapendekin alfa inbakicept-pmln
Brand ANKTIVA
Route INTRAVESICAL
Formulation SOLUTION

Frequently asked questions

What is nogapendekin alfa inbakicept-pmln?

nogapendekin alfa inbakicept-pmln (ANKTIVA) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravesical. Current US regulatory status: approved.

What is the brand name for nogapendekin alfa inbakicept-pmln?

ANKTIVA is a marketed brand name for nogapendekin alfa inbakicept-pmln. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of nogapendekin alfa inbakicept-pmln?

nogapendekin alfa inbakicept-pmln has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.